title: Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution.
abstract: OBJECTIVE
  To assess the utilities and drawbacks of the 7th edition of the TNM classification for lung cancer.
  
  
  METHODS
  Subjects included 1,469 patients who underwent pulmonary resection for primary non-small cell lung cancer. Survival characteristics were compared using the 6th and 7th editions of the staging system.
  
  
  RESULTS
  According to the 6th and 7th editions, respectively, the 5-year survival rates based on stages were as follows: pStage IA (81.0, 81.0 %), pStage IB (70.6, 72.0 %), pStage IIA (61.3, 59.7 %), pStage IIB (56.6, 47.2 %), pStage IIIA (43.4, 37.6 %), pStage IIIB (8.9, 14.9 %), and pStage IV (14.0, 8.0 %). According to the 6th edition, there was no significant difference between pStages IB and IIA (P = 0.268), or between pStages IIA and IIB (P = 0.622), or between pStages IIIB and IV (P = 0.737). According to the 7th edition, there were significant differences between each adjacent stage group, except between pStages IIIB and IV (P = 0.424). According to the 7th edition staging system, 5-year survival rates by T classification were as follows: pT1a, 81.6 %; pT1b, 75.9 %; pT2a, 60.1 %; pT2b, 44.7 %; pT3, 24.4 %; and pT4, 13.2 %; with significant differences between each adjacent pT classification. The 5-year survival rates by M classification were as follows: M0, 57.2 %, M1a, 9.1 %, M1b, 0 %, with a significant difference between M0 and M1a, but there was no significant difference between M1a and M1b.
  
  
  CONCLUSIONS
  The UICC 7th edition staging system is considered valid for non-small cell lung cancer patients and appears to be superior in defining different prognostic groups than the 6th edition.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52, Fucheng Avenue, Haidian District, Beijing, 100142, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Wang
authors.forename: Nan
authors.initials: N
authors.lastname: Wu
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Zheng
authors.forename: Yuan
authors.initials: Y
authors.lastname: Feng
authors.forename: Shi
authors.initials: S
authors.lastname: Yan
authors.forename: Chao
authors.initials: C
authors.lastname: Lv
authors.forename: Shaolei
authors.initials: S
authors.lastname: Li
authors.forename: Yuzhao
authors.initials: Y
authors.lastname: Wang
authors.forename: Yue
authors.initials: Y
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification* / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D055815:Young Adult